Cellectis

Health careALCLSFR0010425595

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

Filings

43 filings

All Inside information43 Voting rights and capital39 Earnings release8 Quarterly financial information8 Annual financial report2 Half-year financial report2

30/07/2026
Cellectis to Report Second Quarter Financial Results on August 6, 2026
Inside informationFR
25/06/2026
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Inside informationFR
11/06/2026
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Inside informationFR
09/06/2026
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Inside informationFR
20/05/2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Inside informationFR
12/05/2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Inside informationFR
27/04/2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Inside informationFR
13/04/2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Inside informationFR
12/03/2026
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
Inside informationFrench
08/01/2026
Cellectis Announces 2026 Strategy and Catalysts
Inside informationFR
15/12/2025
Cellectis Announces Arbitral Decision in Dispute with Servier
Inside informationFR
08/12/2025
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Inside informationFR
27/11/2025
Cellectis organise un webinaire dédié aux actionnaires français le jeudi 4 décembre 2025
Inside informationFrench
19/11/2025
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
Inside informationFR
03/11/2025
Cellectis to Present a Development Update for eti-cel at ASH 2025
Inside informationFR
16/10/2025
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Inside informationFR
16/10/2025
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Inside informationFR
07/10/2025
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
Inside informationFR
28/07/2025
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
Inside informationFR
26/06/2025
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Inside informationFR
21/05/2025
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
Inside informationFR
28/04/2025
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
Inside informationFrench
28/04/2025
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Inside information
07/03/2025
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2024 le 13 mars 2025
Inside informationFrench

About

ISIN: FR0010425595
Ticker: ALCLS
LEI: 5493000KKX5VQ37Q2W83
Sector: Health care
Founded: 1999
Country of registration: FR
Last filing: 06/08/2026, 22:30

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive